CTM Boost
ApprovedBiologic
CTM Boost is one of 23 biologic programs targeting Tendinopathy. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Tendinopathy
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Arcoxia
NovartisApproved
Cosentyx
NovartisPhase 3
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Phase 3
Restasis
TTaiwan Bio Therapeutics Inc.
Phase 3
Whole Blood
VVersailles Hospital
Approved
Ketalar
HHelse Møre og Romsdal HF
Phase 3
Xylocaine
MMEDRx USA, Inc.
Phase 2
Genotropin
EMD SeronoPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tendinopathy1 trial
Connective Tissue Matrix for Rotator Cuff Tendinopathy
Active, not recruiting·—·Phase 4·NCT06160427·92 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CTM Boost. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details